PDF(Pubmed)
Abstract：
OBJECTIVE: To evaluate the difference in the diagnostic efficacy of 18F-PSMA-1007 PET/CT and pelvic MRI in primary prostate cancer, as well as the correlation between the two methods and histopathological parameters and serum PSA levels.
METHODS: A total of 41 patients with suspected prostate cancer who underwent 18F-PSMA-1007 PET/CT imaging in our department from 2018 to 2023 were retrospectively collected. All patients underwent 18F-PSMA-1007 PET/CT and MRI scans. The sensitivity, PPV and diagnostic accuracy of MRI and 18F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were calculated after comparing the results of MRI and 18F-PSMA-1007 PET/CT with biopsy. The Spearman test was used to calculate the correlation between 18F-PSMA-1007 PET/CT, MRI parameters, histopathological indicators, and serum PSA levels.
RESULTS: Compared with histopathological results, the sensitivity, PPV and diagnostic accuracy of 18F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were 95.1%, 100.0% and 95.1%, respectively. The sensitivity, PPV and diagnostic accuracy of MRI in the diagnosis of prostate cancer were 82.9%, 100.0% and 82.9%, respectively. There was a mild to moderately positive correlation between Gleason (Gs) score, Ki-67 index, serum PSA level and 18F-PSMA-1007 PET/CT parameters (p < 0.05). There was a moderately negative correlation between the expression of AMACR (P504S) and 18F-PSMA-1007 PET/CT parameters (p < 0.05). The serum PSA level and the Gs score were moderately positively correlated with the MRI parameters (p < 0.05). There was no correlation between histopathological parameters and MRI parameters (p > 0.05).
CONCLUSIONS: Compared with MRI, 18F-PSMA-1007 PET/CT has higher sensitivity and diagnostic accuracy in the detection of malignant prostate tumors. In addition, the Ki-67 index and AMACR (P504S) expression were only correlated with 18F-PSMA-1007 PET/CT parameters. Gs score and serum PSA level were correlated with 18F-PSMA-1007 PET/CT and MRI parameters. 18F-PSMA-1007 PET/CT examination can provide certain reference values for the clinical diagnosis, evaluation, and treatment of malignant prostate tumors.
METHODS: A total of 41 patients with suspected prostate cancer who underwent 18F-PSMA-1007 PET/CT imaging in our department from 2018 to 2023 were retrospectively collected. All patients underwent 18F-PSMA-1007 PET/CT and MRI scans. The sensitivity, PPV and diagnostic accuracy of MRI and 18F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were calculated after comparing the results of MRI and 18F-PSMA-1007 PET/CT with biopsy. The Spearman test was used to calculate the correlation between 18F-PSMA-1007 PET/CT, MRI parameters, histopathological indicators, and serum PSA levels.
RESULTS: Compared with histopathological results, the sensitivity, PPV and diagnostic accuracy of 18F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were 95.1%, 100.0% and 95.1%, respectively. The sensitivity, PPV and diagnostic accuracy of MRI in the diagnosis of prostate cancer were 82.9%, 100.0% and 82.9%, respectively. There was a mild to moderately positive correlation between Gleason (Gs) score, Ki-67 index, serum PSA level and 18F-PSMA-1007 PET/CT parameters (p < 0.05). There was a moderately negative correlation between the expression of AMACR (P504S) and 18F-PSMA-1007 PET/CT parameters (p < 0.05). The serum PSA level and the Gs score were moderately positively correlated with the MRI parameters (p < 0.05). There was no correlation between histopathological parameters and MRI parameters (p > 0.05).
CONCLUSIONS: Compared with MRI, 18F-PSMA-1007 PET/CT has higher sensitivity and diagnostic accuracy in the detection of malignant prostate tumors. In addition, the Ki-67 index and AMACR (P504S) expression were only correlated with 18F-PSMA-1007 PET/CT parameters. Gs score and serum PSA level were correlated with 18F-PSMA-1007 PET/CT and MRI parameters. 18F-PSMA-1007 PET/CT examination can provide certain reference values for the clinical diagnosis, evaluation, and treatment of malignant prostate tumors.
摘要：
目的：评价18F-PSMA-1007PET/CT和盆腔MRI对原发性前列腺癌的诊断效能差异。以及两种方法与组织病理学参数和血清PSA水平的相关性。
方法：回顾性收集2018年至2023年在我科接受18F-PSMA-1007PET/CT显像的41例疑似前列腺癌患者。所有患者均行18F-PSMA-1007PET/CT和MRI扫描。敏感性,将MRI和18F-PSMA-1007PET/CT结果与活检结果进行比较，计算MRI和18F-PSMA-1007PET/CT在前列腺癌诊断中的PPV和诊断准确性。采用Spearman检验计算18F-PSMA-1007PET/CT,MRI参数,组织病理学指标,和血清PSA水平。
结果：与组织病理学结果相比，灵敏度,18F-PSMA-1007PET/CT诊断前列腺癌的PPV和诊断准确率分别为95.1%,100.0%和95.1%，分别。敏感性,MRI诊断前列腺癌的诊断准确率为82.9%,100.0%和82.9%，分别。格里森(Gs)评分之间存在轻度至中度正相关，Ki-67指数，血清PSA程度和18F-PSMA-1007PET/CT参数(p<0.05)。AMACR(P504S)的表达与18F-PSMA-1007PET/CT参数呈中度负相关(p<0.05)。血清PSA水平和Gs评分与MRI参数呈中度正相关(p<0.05)。组织病理学参数与MRI参数无相关性(p>0.05)。
结论：与MRI相比，18F-PSMA-1007PET/CT对前列腺恶性肿瘤的检出具有较高的敏感度和诊断准确性。此外,Ki-67指数和AMACR(P504S)表达仅与18F-PSMA-1007PET/CT参数相关.Gs评分和血清PSA水平与18F-PSMA-1007PET/CT和MRI参数相关。18F-PSMA-1007PET/CT检查可为临床诊断提供一定的参考价值,评估，和治疗恶性前列腺肿瘤。
方法：回顾性收集2018年至2023年在我科接受18F-PSMA-1007PET/CT显像的41例疑似前列腺癌患者。所有患者均行18F-PSMA-1007PET/CT和MRI扫描。敏感性,将MRI和18F-PSMA-1007PET/CT结果与活检结果进行比较，计算MRI和18F-PSMA-1007PET/CT在前列腺癌诊断中的PPV和诊断准确性。采用Spearman检验计算18F-PSMA-1007PET/CT,MRI参数,组织病理学指标,和血清PSA水平。
结果：与组织病理学结果相比，灵敏度,18F-PSMA-1007PET/CT诊断前列腺癌的PPV和诊断准确率分别为95.1%,100.0%和95.1%，分别。敏感性,MRI诊断前列腺癌的诊断准确率为82.9%,100.0%和82.9%，分别。格里森(Gs)评分之间存在轻度至中度正相关，Ki-67指数，血清PSA程度和18F-PSMA-1007PET/CT参数(p<0.05)。AMACR(P504S)的表达与18F-PSMA-1007PET/CT参数呈中度负相关(p<0.05)。血清PSA水平和Gs评分与MRI参数呈中度正相关(p<0.05)。组织病理学参数与MRI参数无相关性(p>0.05)。
结论：与MRI相比，18F-PSMA-1007PET/CT对前列腺恶性肿瘤的检出具有较高的敏感度和诊断准确性。此外,Ki-67指数和AMACR(P504S)表达仅与18F-PSMA-1007PET/CT参数相关.Gs评分和血清PSA水平与18F-PSMA-1007PET/CT和MRI参数相关。18F-PSMA-1007PET/CT检查可为临床诊断提供一定的参考价值,评估，和治疗恶性前列腺肿瘤。
